Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Exelixis Inc (NQ: EXEL ) 25.88 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Exelixis Inc < Previous 1 2 ... 7 8 9 10 11 12 13 14 Next > Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy December 08, 2022 From Exelixis, Inc. Via Business Wire Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022 December 08, 2022 From Exelixis, Inc. Via Business Wire 3 Stocks to Buy Hand Over Fist in December December 03, 2022 These stocks could be big winners. Via The Motley Fool What 4 Analyst Ratings Have To Say About Exelixis November 02, 2022 Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter: Via Benzinga Exelixis Inks Two Licensing Pacts For Cancer Programs November 02, 2022 Via Benzinga Exelixis (EXEL) Q3 2022 Earnings Call Transcript November 02, 2022 EXEL earnings call for the period ending September 30, 2022. Via The Motley Fool Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022 November 30, 2022 From Exelixis, Inc. Via Business Wire Nasdaq Bear Market: 3 Surefire Growth Stocks to Buy to End the Year Right November 30, 2022 Investors can end the year on a high note by scooping up shares of these bargain-basement-priced growth stocks. Via The Motley Fool The Smartest Stocks to Buy With $20 Right Now November 16, 2022 You don't need a mountain of cash to begin building wealth on Wall Street. Via The Motley Fool 2 No-Brainer Stocks to Buy Right Now for Less than $20 November 12, 2022 These stocks are still bargain-priced but benefit from long-term trends. Via The Motley Fool Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November November 10, 2022 From Exelixis, Inc. Via Business Wire Here's Why This Growth Stock Is Already My 2022 Winner November 09, 2022 Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter. Via The Motley Fool Looking Into Exelixis's Return On Invested Capital November 08, 2022 Pulled from Benzinga Pro data, Exelixis (NASDAQ:EXEL) posted Q3 earnings of $73.21 million, an increase from Q2 of 3.59%. Sales dropped to $411.74 million, a 1.83% decrease between quarters. Via Benzinga Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline November 03, 2022 From Exelixis, Inc. Via Business Wire Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα November 01, 2022 From Exelixis, Inc. Via Business Wire Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan November 01, 2022 From Exelixis, Inc. Via Business Wire Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update November 01, 2022 From Exelixis, Inc. Via Business Wire Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip October 29, 2022 With the Nasdaq Composite down as much as 38% from its peak, these highly innovative companies are ripe for the picking. Via The Motley Fool Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 November 01, 2022 Upgrades Via Benzinga 2 Top Biotech Stocks to Buy for the Long Haul October 28, 2022 Both drugmakers have outperformed the market in the past year. Via The Motley Fool Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022 October 26, 2022 From Exelixis, Inc. Via Business Wire Worried About Rising Interest Rates? These 2 Growth Stocks Could Offer a Solution October 19, 2022 These stocks have low-to-no debt, and analysts see tons of upside. Via The Motley Fool Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022 October 18, 2022 From Exelixis, Inc. Via Business Wire The Smartest Stocks to Buy With $20 Right Now October 14, 2022 Cheap stocks have the ability to generate enormous, long-term profits for investors. Via The Motley Fool These 7 Biotech Stocks Are Set to Boom in 2023 October 10, 2022 This article looks at seven biotech stocks that look like good options to move significantly higher in 2023 Via InvestorPlace Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial October 04, 2022 From Exelixis, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022 October 18, 2022 Upgrades Via Benzinga 3 Biotech Stocks to Buy Now for Extraordinary Gains September 20, 2022 These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market. Via InvestorPlace Exelixis' XL092/ Atezolizumab Shows Encouraging Efficacy, Safety In Heavily Pretreated Cancer Patients September 12, 2022 Via Benzinga Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022 September 10, 2022 From Exelixis, Inc. Via Business Wire < Previous 1 2 ... 7 8 9 10 11 12 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.